ZIOP Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (27 jan 2022 @ 06:00):

Stats
Dagens volum	2.13M
Gjennomsnittsvolum	2.36M
Markedsverdi	208.12M
EPS	$0 ( 2022-02-23 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.07
ATR14	$0.104 (12.01%)

Insider Trading

Date	Person	Action	Amount	type
2021-12-22	De Groot Eleanor	Sell	20 132	Common Stock
2021-03-04	Thistle Mary	Buy	150 000	Stock Option (right to buy)
2021-03-04	Thistle Mary	Buy	37 500	Stock Option (right to buy)
2021-03-04	Thistle Mary	Buy	5 000	Common Stock
2021-03-04	Buchi J Kevin	Buy	31 250	Stock Option (right to buy)

INSIDER POWER
0.00
Last 95 transactions
Buy: 4 516 054 \| Sell: 1 683 458

Volum Korrelasjon

Lang: 0.25 (neutral)

Kort: 0.41 (neutral)

Signal:(38.327) Neutral

ZIOPHARM Oncology Inc Korrelasjon

10 Mest positive korrelasjoner
TLGT	0.939
JAGX	0.926
OLB	0.923
ALLR	0.922
MICS	0.922
FCBC	0.92
ONEM	0.917
AKTX	0.916
BWB	0.915
PSHG	0.914

10 Mest negative korrelasjoner
ITAQU	-0.963
CSLM	-0.949
OPRA	-0.945
SCRM	-0.942
VCTR	-0.942
RCEL	-0.941
XPAX	-0.941
COCO	-0.939
BRLI	-0.938
ALSA	-0.936

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

ZIOPHARM Oncology Inc Korrelasjon - Valuta/Råvare

-0.47
( neutral )

-0.83
( strong negative )

0.00
( neutral )

-0.30
( neutral )

-0.76
( moderate negative )

0.75
( moderate )

ZIOPHARM Oncology Inc Økonomi

Annual	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.380

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.380

FY	2019
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.700

FY	2018
Omsetning:	$146 000
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.370

Financial Reports:

No articles found.

ZIOPHARM Oncology Inc

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.